A recent decision from a federal court in Delaware has preserved a patent for Astellas Pharma’s bladder medication, Myrbetriq. The ruling came after a bench trial, in which the court concluded that Lupin and Zydus Pharmaceuticals, generic-drug manufacturers challenging the patent, had not met the stringent standard of showing “by clear and convincing evidence” that the patent is invalid. This decision fortifies Astellas Pharma’s position in controlling the market for this bladder medication, a significant outcome given the ongoing competition in the pharmaceutical industry. For further details, visit the original article here.